Q1 2023 Follow #BBCIC in



#### A Note from the Executive Director

I am THRILLED to announce that BBCIC was awarded a grant funded by the FDA to assess use of real-world data to support regulatory requirements for interchangeable biosimilars! See below for more information. We are honored to be selected to conduct this important work!

In typical form, 2023 has started with a flurry of activity at BBCIC! We are wrapping up the reports and final manuscripts marking the conclusion of our first, admittedly ambitious, comparative safety and effectiveness study of granulocyte-colony stimulation factor products (filgrastim and pegfilgrastim originators and biosimilars). We are in the middle of executing on the Switching Descriptive Analysis protocol we finalized in early 2022. We are finishing up analyses and manuscripts for three utilization analyses — insulins, bevacizumab, and trastuzumab — and making decisive progress on work related to our first federal grant!

Read the full letter.

#### In the News

## **BBCIC Wins Grant by the FDA**

BBCIC was awarded a grant funded by the US Food and Drug Administration (Award Number U01FD007757) as part of their Regulatory Science research program under the current BsUFA 3 authorization.

The award provides \$1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.

The study—entitled "Improving the Efficiency of Regulatory Decisions for Biosimilars and Interchangeable Biosimilars by Leveraging Real-World Data to Produce Real-World Evidence"—reflects BBCIC's longstanding commitment to evaluating the safety and effectiveness of biologics, including biosimilars, through the generation of reliable, real-world data (RWD) and evidence (RWE).

This project is actively underway!

## New Publication

We are pleased to announce our latest manuscript entitled "Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm" has been accepted for publication by the Journal of Medical Economics!

Once published, it will be available online.

### Current Research


Please visit our research page for descriptions and status of our current and upcoming research!

# Visit Us at AMCP 2023


BBCIC will have a booth in the Expo hall at the AMCP 2023 meeting on March 21-24 in San Antonio, Texas.

Come see us

### **Abstract Tracker**



## **Manuscript Tracker**



Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) | bbcic.org

Address 675 N Washington Street Suite 220 Alexandria, VA 22314